Onconetix, Inc.
NNASDAQ:ONCORecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Onconetix, Inc. Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for men's health and oncology. The company offers Entadfi, an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a prostate disorder; Proclarix, an advanced in vitro protein-based blood diagnostic test approved for sale in the European Union under the In Vitro Diagnostic Regulation for screening and diagnosis of prostate cancer in men with indeterminate prostate-specific antigen levels, which utilizes the same blood sample as standard PSA tests; and associated clinician services through its pipeline in oncology therapeutics and diagnostics. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix operates primarily in the United States and European Union, with its wholly owned subsidiary Proteomedix AG supporting diagnostic commercialization and a license agreement with Labcorp for Proclarix development and distribution. Recent developments include the September 2025 licensing by Proteomedix of manufacturing intellectual property to Immunovia AB for pancreatic cancer diagnostics reagents; a July 2025 definitive merger agreement with Ocuvex Therapeutics, Inc. to acquire its ophthalmic assets including the FDA-approved Omlonti for ocular hypertension and glaucoma, expected to close in Q4 2025 pending approvals; an April 2025 non-binding letter of intent preceding the Ocuvex merger; a name change from Blue Water Biotech, Inc.; and October 2024 financing via a $2.0 million private placement of Series C preferred stock and warrants plus a $25 million equity line of credit.
Company News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
Realbotix LLC Announces Bridge Loan from Onconetix
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Realbotix Corp. Provides Corporate Structure and Operations Update
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Onco-Innovations Announces Non-Brokered LIFE Offering
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
Realbotix Reports Financial Results for Q2-2026
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
Realbotix Provides Update on Nasdaq Listing
Realbotix Provides Update on Nasdaq Listing
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?